HAWTHORNE, N.Y., Mar 13, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Etodolac Extended-Release
HAWTHORNE, N.Y., Feb 20, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd.(NASDAQ:TARO): 2002 Highlights Q4 Sales Increase 43% to $61,976,000 Q4 Gross Profit Increases 38% to $38,541,000 Q4 Net Income Increases 32% to $12,925,000, or $0.44 per Diluted Share 2002 Sales Increase 42% to
HAWTHORNE, N.Y., Feb 18, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) today announced that its Irish affiliate, Taro Pharmaceuticals Ireland Ltd., has entered into an agreement to acquire a multi-purpose pharmaceutical manufacturing and research facility in
HAWTHORNE, N.Y., Feb 12, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) intends to report financial results for the fourth quarter and full year ended December 31, 2002 prior to the Nasdaq market opening on Thursday, February 20, 2003.
HAWTHORNE, N.Y., Feb 3, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) today announced that the Company will present at the Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference at the Grand Hyatt New York hotel.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jan. 16, 2003--Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) announced today that its U.S. affiliate has established a new TaroPharma division to promote proprietary prescription pharmaceutical products in the U.S., and hired a team of professional medical
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Dec. 19, 2002--Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) reported today that the Company has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Ketoconazole Cream, 2%
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Dec. 12, 2002--Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS:TARO) today announced that it has filed a patent application for the use of T2000 in the treatment of essential tremor. T2000 is Taro's patented, novel, long-acting, non-sedating barbiturate compound.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Nov. 26, 2002--Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) reported today that the Company has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Econazole Nitrate Cream 1%
HAWTHORNE, N.Y., Oct 24, 2002 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) 3rd Quarter 2002 Highlights: - Sales Increase 35% to $55.5 Million - Net Income Increases 58% to $11.6 Million, or $0.39 Per Diluted Share - Facility Acquired for New U.S.
Alerts are e-mailed to you whenever certain new company information is posted to this site.
